PDE5 compositions and methods for immunotherapy
AssigneeObsidian Therapeutics, Inc.
InventorsVipin Suri, Byron Delabarre, Michael N. Gladstone, Celeste Richardson, Brian Dolinski, Abhishek Kulkarni, Mara Christine Inniss, Dexue Sun, Dan Jun Li, Grace Y. Olinger, Scott Francis Heller
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the regulated and controlled expression of proteins. Methods for inducing anti-cancer immune responses in a subject are also provided.
Claims26
A composition comprising an effector module, said effector module comprising a stimulus response element (SRE) and at least one payload which is operably linked to said SRE, wherein the SRE comprises a destabilizing domain (DD), said DD comprising, in whole or in part, a cGMP-specific 3′,5′-cyclic phosphodiesterase (hPDE5;
- SEQ ID NO:
- 1) which is capable of ligand binding, and further comprising a mutation in the amino acid at position 732 (R732) of SEQ ID NO:
- 1.
A composition comprising an effector module, said effector module comprising a stimulus response element (SRE) and at least one payload which is operably linked to said SRE, wherein the SRE comprises a destabilizing domain (DD), wherein the DD comprises the catalytic domain of hPDE5 (SEQ ID NO:
- 3) which is capable of ligand binding, and comprises a mutation in the amino acid at the position corresponding to amino acid 732 (R732) of SEQ ID NO:
- 1.
Dependencies are inferred from the claim text.